Difference between revisions of "Abiraterone (Zytiga)"
(Created page with "'''FDA approved 4/28/2011''' ==General information== Class/mechanism: .<ref name="insert">[http://www.campath.com/pdfs/2009-08-Campath%20US%20PI.pdf Alemtuzumab (Campath) packag...") |
|||
| Line 2: | Line 2: | ||
==General information== | ==General information== | ||
| − | Class/mechanism: .<ref name="insert">[http://www. | + | Class/mechanism: Antiandrogen, androgen biosynthesis inhibitor. Inhibits the 17 α-hydroxylase/C17,20-lyase (CYP17) enzyme that is required for androgen biosynthesis, leading to a decrease in androgen production in testicular, adrenal, and prostate tumor tissues..<ref name="insert">[http://www.zytiga.com/downloads/full_product_information.pdf Abiraterone (Zytiga) package insert]</ref><ref>[http://hemonc.org/docs/packageinsert/abiraterone.pdf Abiraterone (Zytiga) package insert (locally hosted backup)]</ref> |
<br>Route: PO | <br>Route: PO | ||
<br>Extravasation: n/a | <br>Extravasation: n/a | ||
| Line 9: | Line 9: | ||
==Patient drug information== | ==Patient drug information== | ||
| − | + | *[http://www.uptodate.com/contents/abiraterone-patient-drug-information Abiraterone (Zytiga) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/abiraterone-patient-drug-information Abiraterone (Zytiga) patient drug information (UpToDate)]</ref> | |
| − | *[http://www.uptodate.com/contents/ | ||
==References== | ==References== | ||
<references/> | <references/> | ||
Revision as of 04:37, 11 January 2012
FDA approved 4/28/2011
General information
Class/mechanism: Antiandrogen, androgen biosynthesis inhibitor. Inhibits the 17 α-hydroxylase/C17,20-lyase (CYP17) enzyme that is required for androgen biosynthesis, leading to a decrease in androgen production in testicular, adrenal, and prostate tumor tissues..[1][2]
Route: PO
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the package insert[1].